Auxilium On a Roll ...
Health Care: Drugs
Biocryst Pharmaceuticals (BCRX: NASDAQ)
$3.11 0.19 | 6.51%
06/04/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 16.44M | 13.62M | 41.12M | 22.34M |
| Receivables | 5.83M | 30.23M | 33.72M | 11.98M |
| Inventories | 263.00K | 898.08K | 6.28M | 0.00 |
| Other Current Assets | 1.74M | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 52.86M | 87.42M | 111.02M | 75.02M |
| Property, Plant & Equipment, Gross | 14.87M | 14.81M | 16.52M | 15.92M |
| Accumulated Depreciation & Depletion | 13.77M | 12.88M | 12.65M | 11.03M |
| Property, Plant & Equipment, Net | 1.10M | 1.93M | 3.87M | 4.88M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 22.82M | 11.77M | 24.67M | 4.79M |
| Total Non-Current Assets | 29.35M | 22.03M | 31.17M | 9.67M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 82.21M | 109.45M | 142.19M | 84.69M |
| Accounts Payable | 2.50M | 8.20M | 18.07M | 5.27M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 52.54K | 52.54K | 40.00K |
| Total Current Liabilities | 26.30M | 27.82M | 37.25M | 17.11M |
| Long Term Debt | 30.00M | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 177.61K | 230.14K | 0.00 |
| Other Non-Current Liabilities | 11.10M | 15.94M | 18.44M | 21.16M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 41.10M | 16.12M | 18.67M | 21.16M |
| Total Liabilities | 67.40M | 43.94M | 55.92M | 38.27M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 14.81M | 65.50M | 86.27M | 46.43M |
| Common Par | 457.00K | 449.59K | 439.07K | 382.75K |
| Additional Paid In Capital | 367.83M | 361.52M | 348.57M | 295.21M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -353.52M | -296.57M | -262.72M | -249.27M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 40.00K | 105.71K | -25.78K | 103.51K |
| Total Capitalization | 44.81M | 65.50M | 86.27M | 46.43M |
| Total Equity | 14.81M | 65.50M | 86.27M | 46.43M |
| Total Liabilities & Stock Equity | 82.21M | 109.45M | 142.19M | 84.69M |
| Total Common Shares Outstanding | 45.66M | 44.96M | 43.91M | 38.28M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 45.14M | 44.56M | 38.93M | 38.06M |
| Diluted Weighted Shares Outstanding | 45.14M | 44.56M | 38.93M | 38.06M |
| Number of Employees | 75 | 76 | 79 | 80 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with BCRX
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- Usertech
- Userrio grande
- UserDebbie0913 Portfolio 1
- UserPART 7 JPMorgan 28th Annual...
- UserSolana Partners
- UserLatest 2009
- ContributorFast Money's 3 Buys & 4...
- User10 shots
- ContributorCramer's Healthcare Stock Buys
Latest BCRX Headlines from TheStreet
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- Biotech Stock Mailbag: Vivus, Chelsea, BioCryst 02.17.12 | 05:02 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- Biocryst's Gout Drug Fails to Impress 10.05.11 | 11:10 am
- Dendreon's Blowup Spreads Across Biotech 08.04.11 | 10:08 am
- Biotech Stock Mailbag: Vivus 09.24.10 | 07:09 am
- BioCryst Tripped Up by Downgrade 09.23.10 | 04:09 pm
- Savient: Drug Approval or Another Delay? 09.10.10 | 08:09 am
- Biotech Calendar: Key Dates for September 09.01.10 | 07:09 am
- BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 04.28.10 | 06:04 pm
Press Releases for BCRX
- BioCryst To Present At Two Upcoming Investor Conferences - Business Wire 05.22.12 | 06:05 am
- BioCryst Provides Corporate Update And Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 06:05 am
- BioCryst To Report First Quarter 2012 Financial Results On May 7, 2012 - Business Wire 04.25.12 | 06:04 am
- BioCryst To Present At Two Upcoming Investor Conferences - Business Wire 02.23.12 | 06:02 am
- BioCryst Reports Fourth Quarter And Full Year 2011 Financial Results - Business Wire 02.16.12 | 06:02 am
- BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C - Business Wire 02.15.12 | 06:02 am
- BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012 - Business Wire 02.06.12 | 06:02 am
- Nancy Hutson Appointed To BioCryst’s Board Of Directors - Business Wire 01.19.12 | 06:01 am
- BioCryst Announces Positive Results From Its Ongoing BCX4208 Phase 2B Study In Patients With Gout - Business Wire 01.08.12 | 05:01 pm
- BioCryst Pharmaceuticals Presents New BCX4208 Gout Data At The 2011 ACR/ARHP Annual Scientific Meeting - Business Wire 11.08.11 | 06:11 am
Partner Headlines for BCRX
- Today's Market News To Trade On: 5 Stocks Making News - Seeking Alpha 03.23.12 | 08:03 am
- UPDATE: Bird Flu Found in the Netherlands - Benzinga 03.19.12 | 01:03 pm
- Noteworthy Institutional 5% Ownership Filings Last Week - Seeking Alpha 03.19.12 | 09:03 am
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- Biotechs And Their Trials By Fire - Seeking Alpha 11.07.11 | 09:11 am
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 11.04.11 | 09:11 am
- BioCryst Pharmaceuticals To Present New Peramivir Data at the 51st Annual ICAAC Meeting - Benzinga 09.17.11 | 06:09 pm
- A Bullish Speculative Options Bet and a Bearish One - Seeking Alpha 06.30.11 | 09:06 am
- 7 Speculative Healthcare Stocks to Rejuvenate Your Portfolio - Seeking Alpha 05.31.11 | 08:05 am
- UPDATE 1-BioCryst says influenza drug lowers virus concentration - Reuters 01.13.11 | 08:01 am
